Literature DB >> 23391869

The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease.

Aikaterini Margariti1, Melanie Deutsch, Spilios Manolakopoulos, Dina Tiniakos, George V Papatheodoridis.   

Abstract

GOALS/
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, but it may also be present in lean individuals. We evaluated the characteristics of NAFLD patients, focusing on those with normal body mass index (BMI). STUDY: One hundred and sixty-two of 185 consecutive NAFLD patients were included. Demographic, clinical, somatometric, and laboratory characteristics were recorded. BMI<25 kg/m2 was considered to be normal.
RESULTS: Of the 162 patients, 12% had normal BMI. Patients with normal compared with those with increased BMI fulfilled more frequently no criterion of metabolic syndrome (43% vs. 2%; P<0.001) and had higher median alanine aminotransferase (92 vs. 62 IU/L; P=0.032) and aspartate aminotransferase levels (45 vs. 37 IU/L; P=0.036). Liver stiffness values by transient elastography were significantly lower in patients with normal than in those with increased BMI (5.0 ± 1.6 vs. 9.5 ± 8.7 kPa; P=0.003). In the 56 patients with liver biopsy, the prevalence of nonalcoholic steatohepatitis (50% vs. 68.8%; P=0.423) and the severity of inflammation and fibrosis did not significantly differ between cases with normal and those with increased BMI.
CONCLUSIONS: Approximately 1 of 8 NAFLD patients coming to a Greek tertiary liver center has normal BMI. On liver biopsy, normal BMI patients often have nonalcoholic steatohepatitis and histologic liver lesions of similar severity to the overweight or obese patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391869     DOI: 10.1097/MCG.0b013e31826be328

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

1.  Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.

Authors:  Gabriella V Hernandez; Victoria A Smith; Megan Melnyk; Matthew A Burd; Kimberly A Sprayberry; Mark S Edwards; Daniel G Peterson; Darin C Bennet; Rob K Fanter; Daniel A Columbus; Juan P Steibel; Hunter Glanz; Chad Immoos; Margaret S Rice; Tasha M Santiago-Rodriguez; Jason Blank; Jennifer J VanderKelen; Christopher L Kitts; Brian D Piccolo; Michael R La Frano; Douglas G Burrin; Magdalena Maj; Rodrigo Manjarin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-31       Impact factor: 4.052

2.  Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease.

Authors:  Norelle R Reilly; Benjamin Lebwohl; Rolf Hultcrantz; Peter H R Green; Jonas F Ludvigsson
Journal:  J Hepatol       Date:  2015-01-21       Impact factor: 25.083

3.  Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.

Authors:  Qianyi Wang; Hong You; Xiaojuan Ou; Xinyan Zhao; Yameng Sun; Min Wang; Ping Wang; Yu Wang; Weijia Duan; Xiaoming Wang; Shanshan Wu; Yuanyuan Kong; Romil Saxena; Annette S H Gouw; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-26       Impact factor: 6.047

4.  Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice.

Authors:  Lan N Tu; Megan R Showalter; Tomas Cajka; Sili Fan; Viju V Pillai; Oliver Fiehn; Vimal Selvaraj
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

5.  Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.

Authors:  Chiara Gelli; Mirko Tarocchi; Ludovico Abenavoli; Laura Di Renzo; Andrea Galli; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2017-05-07       Impact factor: 5.742

Review 6.  Non-alcoholic fatty liver disease in lean individuals.

Authors:  Somaya Albhaisi; Abhijit Chowdhury; Arun J Sanyal
Journal:  JHEP Rep       Date:  2019-08-30

7.  Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

Authors:  Lampros Chrysavgis; Eleftheria Ztriva; Adonis Protopapas; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

8.  Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study.

Authors:  Fakhar Ali Qazi-Arisar; Raj Uchila; Catherine Chen; Cathy Yang; Shi-Yi Chen; Ravikiran Sindhuvalada Karnam; Amirhossein Azhie; Wei Xu; Zita Galvin; Nazia Selzner; Leslie Lilly; Mamatha Bhat
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

9.  Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.

Authors:  Shujun Zhang; Tingting Du; Mengni Li; Jing Jia; Huiming Lu; Xuan Lin; Xuefeng Yu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 10.  NAFLD in normal weight individuals.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Diabetol Metab Syndr       Date:  2022-03-24       Impact factor: 5.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.